Women make up nearly two-thirds of Alzheimer's cases in the United States, a gap that's long been chalked up simply to women living longer on average. But that explanation doesn't fully hold up, and a growing body of research points somewhere more specific: a unique neuroendocrine transition that happens only in women, during the shift from perimenopause into menopause.
This connection has prompted researchers to look more closely at what happens to the brain during the menopausal transition, rather than viewing Alzheimer's risk solely as a problem that begins much later in life. The years around menopause may represent an important period when metabolic, hormonal, and neurological changes begin occurring simultaneously.
That doesn't mean every woman going through perimenopause is destined to develop cognitive decline or Alzheimer's disease. It does suggest, however, that the hormonal transition deserves greater attention as part of a woman's overall long-term health strategy.
Dr. Lisa Mosconi, associate director of the Alzheimer's Prevention Clinic and the researcher behind some of the most detailed work in this area, led a study examining brain bioenergetics, essentially, how efficiently the brain is using energy, in nearly fifty women between the ages of 40 and 60, spanning different stages of the menopausal transition. The pattern was striking: metabolic abnormalities were lowest in premenopausal women, intermediate in perimenopausal women, and most pronounced in women who had reached menopause. Women in the perimenopausal and menopausal groups also showed early signs of amyloid plaque, the protein buildup closely associated with Alzheimer's disease. None of the men studied alongside them showed the same pattern.
"Estrogen is a protective hormone that actually goes inside a woman's brain, stimulating growth, health, and plasticity, and keeping it expanding rather than shrinking as a woman ages," Mosconi has explained. When estrogen naturally declines during this transition, that protective effect declines with it.
The significance of this research lies partly in when these changes appear. Rather than identifying neurological changes only after cognitive symptoms have developed, the research suggests that measurable changes in brain metabolism may occur during the hormonal transition itself. This gives researchers a potential opportunity to study brain health much earlier than has traditionally been possible.
Estrogen receptors are present throughout the brain, including areas involved in memory, learning, mood, and energy regulation. As estrogen levels fluctuate and eventually decline during perimenopause and menopause, researchers are investigating how those changes may influence these systems. This may also help explain why some women notice changes in concentration, memory, sleep, or mood during the same period.
Importantly, the presence of amyloid or changes in brain metabolism does not mean that a woman will necessarily develop Alzheimer's disease. These are markers researchers are studying as part of a much larger and more complicated disease process.
The timing revealed in this research matters as much as the finding itself. Because the bioenergetic deficits appear to track closely with the endocrine aging process, specifically the perimenopausal and menopausal transition, that window looks like the optimal point for medical intervention, rather than waiting until symptoms of cognitive decline are already apparent years later. This is part of why practitioners, including Dr. Lionel Bissoon at Liondale Medical, have shifted toward starting hormone-focused prevention conversations earlier, often around age 40 to 50, rather than only addressing hormonal symptoms reactively once they've become disruptive.
Perimenopause can begin years before a woman's final menstrual period, and hormone levels may fluctuate considerably during this period. That means the transition is not necessarily a single event. It is a prolonged biological process that can affect sleep, mood, metabolism, reproductive health, and other aspects of wellbeing.
For that reason, conversations about hormone health do not necessarily need to begin when menopause is complete. A woman experiencing changes in her cycle alongside new symptoms such as sleep disruption, mood changes, fatigue, or cognitive complaints may benefit from discussing those changes with a qualified physician.
The potential value of earlier evaluation is not limited to Alzheimer's prevention. Understanding where a woman is in the menopausal transition can also help physicians distinguish hormonal symptoms from other conditions that may require separate investigation.
At the same time, hormone therapy decisions should be individualized. Age, menopausal status, symptoms, medical history, family history, medications, and personal risk factors all matter when determining whether hormone therapy is appropriate.
At Liondale Medical, bioidentical hormone replacement therapy uses hormones with the same molecular structure as those your body naturally produces, which is part of why they're generally well tolerated. We use this approach to treat symptoms of perimenopause, menopause, and thyroid-related hormone imbalance, hot flashes, night sweats, memory changes, and mood swings, which for some women can begin as early as their 30s. We also see women struggling with broader hormone imbalances involving weight gain, fatigue, low libido, and anxiety, symptoms that often get dismissed as ordinary stress rather than investigated as a hormonal pattern. Every treatment plan is built around the individual patient's labs, symptoms, and goals rather than a standardized protocol.
For a deeper look at the difference between bioidentical hormones and more conventional formulations, and how that distinction actually plays out clinically, see our detailed guide to bioidentical vs. synthetic hormones.
The purpose of evaluating hormone levels and symptoms is not simply to identify a number that falls outside a reference range. Hormone levels naturally change throughout the menopausal transition, and symptoms need to be considered alongside laboratory findings and the patient's overall clinical picture.
For some women, the primary concern may be hot flashes or disrupted sleep. For others, changes in mood, energy, libido, body composition, or concentration may be more noticeable. Looking at these symptoms collectively can provide a more useful picture of how the transition is affecting an individual patient.
It is also important to recognize that hormone therapy is not appropriate for everyone. A physician should review the potential benefits and risks based on the patient's individual circumstances before treatment begins. The goal is to determine whether hormone therapy makes sense as part of a broader health plan, rather than assuming that every woman should receive the same treatment.
Hormone therapy alone isn't the whole strategy the research points toward. The same researchers behind this work also recommend diet changes and consistent exercise alongside hormone therapy starting around age 40, specifically citing that roughly three hours of rigorous exercise per week can increase blood flow to the brain and may help loosen amyloid plaque buildup. At Liondale Medical, whenever we begin hormone therapy with a patient, our physicians pair it with fitness and nutrition guidance and, where appropriate, supplement recommendations, rather than treating hormone therapy as a standalone intervention disconnected from the rest of a patient's health habits.
Exercise can influence several systems that are relevant to healthy aging, including cardiovascular fitness, circulation, metabolic health, sleep, and mood. These factors matter because brain health does not exist independently of the rest of the body. Conditions such as insulin resistance, high blood pressure, obesity, and cardiovascular disease can also influence long-term cognitive health.
Nutrition is similarly part of the broader picture. A balanced dietary pattern that provides adequate protein, fiber, healthy fats, vitamins, and minerals can support metabolic health while helping address deficiencies that may contribute to fatigue or other symptoms. Individual nutritional needs vary, however, and supplementation is most useful when there is a specific reason to recommend it.
The larger principle is consistency. Hormone health, metabolic health, cardiovascular health, sleep, physical activity, and cognitive health are interconnected, so prevention strategies are generally more meaningful when they address several of these areas rather than focusing on one intervention in isolation.
Because hormonal shifts show up differently from person to person, it helps to know the range of what can signal an imbalance worth investigating. Symptoms we commonly see include headaches, anxiety, hypothyroidism, cold hands and feet, dry hair, weight gain, bloating, irritability, breast tenderness, fibrocystic breast changes, dense breast tissue on mammograms, endometriosis, and depression. None of these symptoms alone confirms a hormonal cause, but taken together, or when several appear around the same time, they're worth bringing to a physician rather than managing individually or attributing to stress alone.
Cognitive changes can be particularly frustrating during this period. Some women describe difficulty concentrating, forgetting words, feeling mentally slower, or struggling to stay focused on tasks that previously felt routine. Sleep disruption and changes in mood can further amplify these experiences.
These symptoms should not automatically be interpreted as evidence of Alzheimer's disease. Many common and treatable factors can affect concentration and memory, including poor sleep, stress, medication effects, nutritional deficiencies, thyroid problems, depression, and hormonal fluctuations.
That is why a broader evaluation can be useful. Rather than assuming that every symptom has one cause, a physician can look for patterns and determine which factors may be contributing to the patient's experience.
It's worth being clear about what this research does and doesn't establish. The studies described here are preclinical and observational, they identify a strong, biologically plausible association between the menopausal transition and changes in brain metabolism and amyloid markers, but they don't yet constitute definitive proof that hormone therapy prevents Alzheimer's disease in every woman who takes it. This is an active area of ongoing research, and Dr. Bissoon discusses the current state of the evidence honestly with patients rather than overstating what's been conclusively proven. What the research does support clearly is that the perimenopausal and menopausal transition is a period of real neurological vulnerability worth taking seriously, and that addressing hormonal changes during this window is a reasonable, evidence-informed part of a broader prevention strategy.
There are still important unanswered questions. Researchers continue to study whether the timing of hormone therapy changes its potential effects on the brain, whether different formulations produce different outcomes, and which patient characteristics may influence the balance of benefits and risks.
This distinction between an association and a proven preventive effect is important. Research showing that menopause-related hormonal changes coincide with changes in brain metabolism provides a compelling reason to investigate the relationship further, but it should not be presented as proof that hormone replacement therapy can eliminate Alzheimer's risk.
For patients, this means the conversation should be individualized and based on the evidence available today. Hormone therapy may be considered for appropriate patients for established menopausal indications, while potential effects on long-term cognitive health remain an area of continued research.
If this research resonates with your own situation, whether you're already in perimenopause or simply want to understand your risk profile before symptoms start, a consultation with Dr. Bissoon begins with a detailed review of your symptoms, family history, and current hormone levels through lab testing. From there, a treatment plan is built specifically around what your labs and symptoms actually show, which may include bioidentical hormone therapy, lifestyle and nutrition guidance, or both together, depending on where you are in the transition and what your goals are.
A consultation can also provide an opportunity to discuss symptoms that may otherwise be treated separately. Changes in sleep, mood, weight, energy, menstrual patterns, libido, and cognitive function can occur together during perimenopause, and looking at them as part of the same clinical picture may provide additional context.
The objective is not simply to start treatment as quickly as possible. It is to understand what is changing, determine which factors may be contributing to those changes, and establish an appropriate plan that can be reassessed as the patient's needs evolve.
For women in their 40s, that conversation may be particularly useful because perimenopause can be a period of significant biological change even before menopause has officially occurred. Understanding those changes earlier can help women make informed decisions about their health and establish a strategy for managing symptoms while also paying attention to long-term wellbeing.
Current research shows a strong association between the hormonal changes of perimenopause and menopause and early markers linked to Alzheimer's risk, and addressing this transition with hormone therapy is a reasonable, evidence-informed preventive step. It isn't yet proven as a guaranteed prevention method for every woman, and Dr. Bissoon discusses the current evidence honestly during consultations.
Based on the research discussed here, many practitioners now start these conversations around age 40 to 50, during the perimenopausal window, rather than waiting until menopause symptoms are already significantly disruptive.
Headaches, anxiety, cold hands and feet, weight gain, bloating, irritability, breast tenderness, and mood changes are all worth mentioning to your provider, especially if several appear together.
No. Research suggests exercise, roughly three hours of rigorous activity weekly, offers independent brain health benefits, including improved blood flow and potential effects on amyloid plaque. At Liondale Medical, hormone therapy is paired with nutrition and fitness guidance rather than treated as a standalone fix.
Not exactly. Bioidentical hormones are molecularly identical to what your body naturally produces, which is different from some conventional synthetic formulations. Our guide to bioidentical vs. synthetic hormones covers this distinction in detail.
Published
